vs
碧迪（BDX）与Ulta Beauty（ULTA）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是Ulta Beauty的1.8倍（$5.3B vs $2.9B），Ulta Beauty净利率更高（8.1% vs 7.3%，领先0.8%），Ulta Beauty同比增速更快（12.9% vs -0.4%），碧迪自由现金流更多（$549.0M vs $-81.6M），过去两年Ulta Beauty的营收复合增速更高（7.2% vs 2.0%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
Ulta Beauty是美国头部美妆连锁品牌，总部位于伊利诺伊州博林布鲁克，旗下门店在售商品覆盖高低端彩妆、香水、美甲、身体护理、美发产品及美妆工具等全品类美妆个护产品，每家门店均配备对外开放的美容沙龙，为消费者提供一站式美妆消费及服务体验。
BDX vs ULTA — 直观对比
营收规模更大
BDX
是对方的1.8倍
$2.9B
营收增速更快
ULTA
高出13.3%
-0.4%
净利率更高
ULTA
高出0.8%
7.3%
自由现金流更多
BDX
多$630.6M
$-81.6M
两年增速更快
ULTA
近两年复合增速
2.0%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $2.9B |
| 净利润 | $382.0M | $230.9M |
| 毛利率 | 45.9% | 40.4% |
| 营业利润率 | 10.5% | 10.8% |
| 净利率 | 7.3% | 8.1% |
| 营收同比 | -0.4% | 12.9% |
| 净利润同比 | 24.0% | -4.7% |
| 每股收益（稀释后） | $1.34 | $5.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXULTA
| Q4 25 | $5.3B | $2.9B | ||
| Q3 25 | $5.9B | $2.8B | ||
| Q2 25 | $5.5B | $2.8B | ||
| Q1 25 | $5.3B | — | ||
| Q4 24 | $5.2B | $2.5B | ||
| Q3 24 | $5.4B | $2.6B | ||
| Q2 24 | $5.0B | $2.7B | ||
| Q1 24 | $5.0B | $3.6B |
净利润BDXULTA
| Q4 25 | $382.0M | $230.9M | ||
| Q3 25 | $493.0M | $260.9M | ||
| Q2 25 | $574.0M | $305.1M | ||
| Q1 25 | $308.0M | — | ||
| Q4 24 | $303.0M | $242.2M | ||
| Q3 24 | $400.0M | $252.6M | ||
| Q2 24 | $487.0M | $313.1M | ||
| Q1 24 | $537.0M | $394.4M |
毛利率BDXULTA
| Q4 25 | 45.9% | 40.4% | ||
| Q3 25 | 47.5% | 39.2% | ||
| Q2 25 | 47.8% | 39.1% | ||
| Q1 25 | 42.8% | — | ||
| Q4 24 | 43.2% | 39.7% | ||
| Q3 24 | 45.7% | 38.3% | ||
| Q2 24 | 46.2% | 39.2% | ||
| Q1 24 | 45.7% | 37.7% |
营业利润率BDXULTA
| Q4 25 | 10.5% | 10.8% | ||
| Q3 25 | 11.8% | 12.4% | ||
| Q2 25 | 16.0% | 14.1% | ||
| Q1 25 | 10.4% | — | ||
| Q4 24 | 8.8% | 12.6% | ||
| Q3 24 | 11.4% | 12.9% | ||
| Q2 24 | 12.1% | 14.7% | ||
| Q1 24 | 14.5% | 14.5% |
净利率BDXULTA
| Q4 25 | 7.3% | 8.1% | ||
| Q3 25 | 8.4% | 9.4% | ||
| Q2 25 | 10.4% | 10.7% | ||
| Q1 25 | 5.8% | — | ||
| Q4 24 | 5.9% | 9.6% | ||
| Q3 24 | 7.4% | 9.9% | ||
| Q2 24 | 9.8% | 11.5% | ||
| Q1 24 | 10.6% | 11.1% |
每股收益（稀释后）BDXULTA
| Q4 25 | $1.34 | $5.14 | ||
| Q3 25 | $1.71 | $5.78 | ||
| Q2 25 | $2.00 | $6.70 | ||
| Q1 25 | $1.07 | — | ||
| Q4 24 | $1.04 | $5.14 | ||
| Q3 24 | $1.37 | $5.30 | ||
| Q2 24 | $1.68 | $6.47 | ||
| Q1 24 | $1.85 | $8.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $204.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $25.3B | $2.6B |
| 总资产 | $54.8B | $7.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BDXULTA
| Q4 25 | $740.0M | $204.9M | ||
| Q3 25 | $641.0M | $242.7M | ||
| Q2 25 | $735.0M | $454.6M | ||
| Q1 25 | $667.0M | — | ||
| Q4 24 | $711.0M | $177.8M | ||
| Q3 24 | $1.7B | $414.0M | ||
| Q2 24 | $4.5B | $524.6M | ||
| Q1 24 | $2.3B | $766.6M |
股东权益BDXULTA
| Q4 25 | $25.3B | $2.6B | ||
| Q3 25 | $25.4B | $2.6B | ||
| Q2 25 | $25.5B | $2.4B | ||
| Q1 25 | $25.2B | — | ||
| Q4 24 | $25.2B | $2.3B | ||
| Q3 24 | $25.9B | $2.3B | ||
| Q2 24 | $25.9B | $2.3B | ||
| Q1 24 | $25.6B | $2.3B |
总资产BDXULTA
| Q4 25 | $54.8B | $7.0B | ||
| Q3 25 | $55.3B | $6.6B | ||
| Q2 25 | $54.9B | $6.0B | ||
| Q1 25 | $54.5B | — | ||
| Q4 24 | $54.7B | $6.0B | ||
| Q3 24 | $57.3B | $5.7B | ||
| Q2 24 | $55.6B | $5.6B | ||
| Q1 24 | $54.2B | $5.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $5.6M |
| 自由现金流经营现金流 - 资本支出 | $549.0M | $-81.6M |
| 自由现金流率自由现金流/营收 | 10.5% | -2.9% |
| 资本支出强度资本支出/营收 | 2.1% | 3.1% |
| 现金转化率经营现金流/净利润 | 1.72× | 0.02× |
| 过去12个月自由现金流最近4个季度 | $2.6B | $-92.2M |
8季度趋势，按日历期对齐
经营现金流BDXULTA
| Q4 25 | $657.0M | $5.6M | ||
| Q3 25 | $1.4B | $96.5M | ||
| Q2 25 | $1.2B | $220.0M | ||
| Q1 25 | $164.0M | — | ||
| Q4 24 | $693.0M | $-56.8M | ||
| Q3 24 | $1.2B | $199.5M | ||
| Q2 24 | $1.3B | $159.3M | ||
| Q1 24 | $514.0M | $1.1B |
自由现金流BDXULTA
| Q4 25 | $549.0M | $-81.6M | ||
| Q3 25 | $1.0B | $19.6M | ||
| Q2 25 | $1.0B | $141.0M | ||
| Q1 25 | $35.0M | — | ||
| Q4 24 | $588.0M | $-171.1M | ||
| Q3 24 | $882.0M | $104.3M | ||
| Q2 24 | $1.1B | $68.3M | ||
| Q1 24 | $380.0M | $994.0M |
自由现金流率BDXULTA
| Q4 25 | 10.5% | -2.9% | ||
| Q3 25 | 17.0% | 0.7% | ||
| Q2 25 | 19.0% | 4.9% | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | 11.4% | -6.8% | ||
| Q3 24 | 16.2% | 4.1% | ||
| Q2 24 | 22.4% | 2.5% | ||
| Q1 24 | 7.5% | 28.0% |
资本支出强度BDXULTA
| Q4 25 | 2.1% | 3.1% | ||
| Q3 25 | 6.0% | 2.8% | ||
| Q2 25 | 3.2% | 2.8% | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 2.0% | 4.5% | ||
| Q3 24 | 5.4% | 3.7% | ||
| Q2 24 | 3.6% | 3.3% | ||
| Q1 24 | 2.7% | 3.5% |
现金转化率BDXULTA
| Q4 25 | 1.72× | 0.02× | ||
| Q3 25 | 2.75× | 0.37× | ||
| Q2 25 | 2.12× | 0.72× | ||
| Q1 25 | 0.53× | — | ||
| Q4 24 | 2.29× | -0.23× | ||
| Q3 24 | 2.94× | 0.79× | ||
| Q2 24 | 2.66× | 0.51× | ||
| Q1 24 | 0.96× | 2.84× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
ULTA
暂无分部数据
